Baseballs Big Cat Retires
Andres Galarraga retires after 19 seasons Tuesday one home run short of 400. "I'm happy," said Galarraga's wife, Eneyda. "He'd like to stay home right now. He's played for a long time. You know when it's time for you to retire."
Galarraga signed a minor-league deal with the New York Mets in December after making his second successful return from non-Hodgkin's lymphoma last season.
He had hoped to join the 400-home run club by finishing his career mainly as a pinch-hitter. He had three home runs and was batting .235 in 17 spring games.
Galarraga missed the 1999 season after he was diagnosed with non-Hodgkin's lymphoma, then hit .302 with 28 home runs and 100 RBIs with Atlanta in 2000.
The disease reoccurred in November 2003. He underwent surgery that month and had a stem cell transplant the following February.
Source: Denver Post
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
